Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ECHTA: EchoCath, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scott bradley who wrote (9)	4/30/2001 10:11:31 AM
From: scott bradley	Respond to of 10

News today Monday April 30, 9:20 am Eastern Time Press Release EchoCath's ColorMark Technologies Licensed PRINCETON, N.J.--(BUSINESS WIRE)--April 30, 2001--EchoCath, Inc. (NASD-OTC:ECHTA) announced today that it has licensed, worldwide and exclusively, its ColorMark(TM) technologies for guiding soft tissue biopsies and cancer therapies to Critical Care Innovations, Inc., a Virginia corporation. Mr. Frank DeBernardis, President, stated that CCI is involved with the development of new, innovative medical devices that enhance the diagnosis and treatment of deep organ, soft-tissue tumors. Mr. DeBernardis also stated, ``We are pleased that our ColorMark(TM) technologies are being integrated into CCI's platform of products. CCI has a clear vision backed by an experienced marketing team that knows how to pioneer the sales of specialty medical devices. Mr. Roger Kolasinski, the founder of CCI, has over thirty years experience in sales and distribution of medical devices; he, along with his team, has a keen eye for opportunities and a determination to succeed. We look forward to a very successful collaboration.'' The two companies have cooperated to develop EchoCath's innovative technology for a wide range of applications in the cancer diagnostic and therapeutic markets. Mr. Kolasinski, CEO of Critical Care Innovations, said that, ``We believe that EchoCath's technology is perfect for our product platform and, with its integration, enhances our opportunities within today's existing managed healthcare environment.'' He noted that CCI is now ``poised to become a leading provider to these important markets'' and that this exclusive license agreement will enable CCI to immediately execute its strategic plans. CCI, located in Chantilly, Virginia, is a developer and marketer of innovative technologies designed for the soft tissue tumor markets. Certain statements herein constitute ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: limited commercial operations; no assurances of success; need for additional financing; uncertainty of market acceptance; failure to receive or delays in receiving regulatory approval; lack of a distribution channel for the Company's products; and limitations on third party reimbursement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Contact: EchoCath, Inc., Princeton Frank DeBernardis, 609/987-8400 x127